(Q28212508)

English

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer

scientific article (publication date: August 2003)

In more languages

Statements

scholarly article

0 references

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

Christian Dittrich

1

0 references

Veronique Dieras

2

0 references

Pierre Kerbrat

3

0 references

Cornelis Punt

4

0 references

Roberto Sorio

5

0 references

Francesco Caponigro

6

0 references

Xavier Paoletti

7

0 references

Christine de Balincourt

8

0 references

Denis Lacombe

9

0 references

Pierre Fumoleau

10

0 references

language of work or name

0 references

publication date

August 2003

0 references

Investigational New Drugs

0 references

21

0 references

3

0 references

347-52

0 references

Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular and molecular determinants of cisplatin resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/14578683

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1025476813365

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28212508&oldid=1393448537"